Transparency
Lab results & certificates of analysis
Independent Janoshik Analytical reports for the lots we stock, published in full and unedited. Every report carries a unique key you can check yourself at janoshik.com/verify.
Verify any report yourself
Each report below is shown exactly as issued, including its QR code and unique verification key. Enter the key at janoshik.com/verify to confirm the result directly with the lab.
Analytical documentation describes the composition of a lot. It is not a representation of safety, efficacy or fitness for any purpose. See our compliance & research use policy.
Open any report right here in the table below — no download needed.
| Compound | Lot | Purity | Endotoxin | Content | Report |
|---|---|---|---|---|---|
| Retatrutide (GLP3) 50 mg 57.63 / 57.93 / 57.03 mg | RT50-260806 | 99.68 / 99.63 / 99.67 % | <1 EU/vial | 57.63 / 57.93 / 57.03 mg | |
| Retatrutide (GLP3) 40 mg 44.93 / 45.35 / 44.70 mg | RT40-260804 | 99.90 / 99.86 / 99.88 % | <1 EU/vial | 44.93 / 45.35 / 44.70 mg | |
| Retatrutide (GLP3) 30 mg 34.94 / 34.27 / 34.47 mg | RT30-260803 | 99.92 / 99.96 / 99.97 % | <1 EU/vial | 34.94 / 34.27 / 34.47 mg | |
| Retatrutide (GLP3) 20 mg 23.82 / 24.26 / 29.29 mg | RT20-260709 | 99.58 / 99.66 / 99.62 % | 1.454 EU/vial | 23.82 / 24.26 / 29.29 mg | |
| Retatrutide (GLP3) 10 mg 11.95 / 11.99 / 12.17 mg | RT10-860805 | 99.92 / 99.96 / 99.97 % | <1 EU/vial | 11.95 / 11.99 / 12.17 mg | |
| Tirzepatide (GLP2) 30 mg 35.57 / 35.48 / 35.04 mg | T30-260830 | 99.94 / 99.96 / 99.98 % | <1 EU/vial | 35.57 / 35.48 / 35.04 mg | |
| Tirzepatide (GLP2) 60 mg 66.90 / 66.64 / 65.95 mg | T60-260812 | 99.47 / 99.52 / 99.47 % | <1 EU/vial | 66.90 / 66.64 / 65.95 mg | |
| Tesamorelin 10 mg 11.60 / 11.57 / 11.79 mg | Tesa-260609 | 98.28 / 98.18 / 98.27 % | 1.464 EU/vial | 11.60 / 11.57 / 11.79 mg | |
| MOTS-c 10 mg 9.92 / 10.16 / 10.40 mg | MS10-260829 | 98.46 / 98.56 / 98.62 % | <1 EU/vial | 9.92 / 10.16 / 10.40 mg | |
| KLOW Blend 80 mg (GHK-Cu / BPC-157 / TB-500 / KPV) GHK-Cu 57.83 / 57.16 / 56.80 mg; BPC-157 11.26 / 11.12 / 11.13 mg; TB-500 10.68 / 10.62 / 10.59 mg; KPV 11.16 / 10.99 / 10.91 mg | KLOW-260831 | Blend content assay (see report) | 9.604 EU/vial | GHK-Cu 57.83 / 57.16 / 56.80 mg; BPC-157 11.26 / 11.12 / 11.13 mg; TB-500 10.68 / 10.62 / 10.59 mg; KPV 11.16 / 10.99 / 10.91 mg | |
| SS-31 (Elamipretide) 10 mg 10.17 / 10.11 / 10.18 mg | SS-260821 | 99.85 / 99.76 / 99.82 % | 3.850 EU/vial | 10.17 / 10.11 / 10.18 mg | |
| KPV 10 mg 11.66 / 11.67 / 11.67 mg | KPV-260822 | 99.46 / 99.44 / 99.58 % | Not requested on this lot | 11.66 / 11.67 / 11.67 mg | |
| DSIP 10 mg 11.96 / 11.54 / 11.16 mg | Dsip-260813 | 98.95 / 98.99 / 98.97 % | 1.475 EU/vial | 11.96 / 11.54 / 11.16 mg | |
| Selank / Semax Blend 20 mg Selank 11.51 / 11.87 / 11.78 mg; Semax 12.13 / 12.34 / 12.43 mg | KX-260727 | Blend content assay (see report) | Not requested on this lot | Selank 11.51 / 11.87 / 11.78 mg; Semax 12.13 / 12.34 / 12.43 mg | |
| GHK-Cu 80 mg 82.10 / 82.16 / 86.25 mg (copper complexed) | GHK100-260604 | Content assay (see report) | 2.065 EU/vial | 82.10 / 82.16 / 86.25 mg (copper complexed) | |
| BPC-157 10 mg 10.48 / 11.43 / 10.18 mg | BPC10260325 | 99.77 / 99.80 / 99.79 % | Not requested on this lot | 10.48 / 11.43 / 10.18 mg | |
| GLOW Blend 70 mg (GHK-Cu / BPC-157 / TB-500) GHK-Cu 57.01 / 58.67 / 59.48 mg; BPC-157 9.91 / 10.18 / 10.33 mg; TB-500 10.08 / 10.39 / 10.52 mg | Glow70260320 | Blend content assay (see report) | — | GHK-Cu 57.01 / 58.67 / 59.48 mg; BPC-157 9.91 / 10.18 / 10.33 mg; TB-500 10.08 / 10.39 / 10.52 mg | |
| NAD+ 500 mg 532.45 / 531.25 / 533.64 mg | NAD260327 | Content assay (see report) | — | 532.45 / 531.25 / 533.64 mg | |
| TB-500 10 mg 10.94 / 11.01 / 10.60 mg | TB-260724 | 99.38 / 99.39 / 99.31 % | 1.597 EU/vial | 10.94 / 11.01 / 10.60 mg | |
| BPC-157 / TB-500 Repair Blend 20 mg BPC-157 12.24 / 11.57 / 11.98 mg; TB-500 11.57 / 11.33 / 11.35 mg | BB-260724 | Blend content assay (see report) | 1.442 EU/vial | BPC-157 12.24 / 11.57 / 11.98 mg; TB-500 11.57 / 11.33 / 11.35 mg | |
| PT-141 (Bremelanotide) 10 mg 11.24 / 10.96 / 11.33 mg | PT-260820 | 99.54 / 99.65 / 99.56 % | 2.763 EU/vial | 11.24 / 10.96 / 11.33 mg | |
| ARA-290 (Cibinetide) 9 mg 8.90 / 9.24 / 9.03 mg | ARA-260818 | 99.23 / 99.21 / 99.22 % | 6.914 EU/vial | 8.90 / 9.24 / 9.03 mg | |
| Cagrilintide 5 mg 5.25 / 5.28 / 5.35 mg | Cag-260727 | 99.84 / 99.80 / 99.78 % | Not requested on this lot | 5.25 / 5.28 / 5.35 mg | |
| Tesamorelin 20 mg 22.21 / 21.16 / 21.15 mg | Tesa-260610 | 99.04 / 98.81 / 98.82 % | 6.123 EU/vial | 22.21 / 21.16 / 21.15 mg |
How to read a report
Content is the measured mass of peptide in each of three vials assayed from the lot. Purity is the main HPLC peak as a percentage of total peak area. Endotoxin is reported per vial by LAL assay.
Why lot matching matters
A report is only useful if it belongs to the vial in your hand. The lot code printed on your label matches one of the lots listed above, so the document applies to your specific batch.
What a report does not say
A certificate of analysis describes what is in a lot. It is not a statement of safety, efficacy or suitability for any use, and it does not authorize use of the material in humans or animals.
Batch documentation is provided for research verification purposes only and does not constitute a claim of safety, efficacy or fitness for any use in humans or animals. Need a report that isn't listed? Contact our lab team.